Minirin Versus Oxybutynin for Nocturnal Enuresis in Children
NCT ID: NCT02538302
Last Updated: 2015-09-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
66 participants
INTERVENTIONAL
2013-07-31
2015-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate in Children and Adolescents With Primary Nocturnal Enuresis (PNE)
NCT00209261
Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence
NCT00909181
Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder
NCT01192568
Transdermal Versus Oral Oxybutynin in Pediatric OAB
NCT07081906
Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis
NCT05617664
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Minirin
120 microgram per day for 2 months, then 60 microgram per day for 2 months, then 60 microgram every two days for two months
Minirin
Minirin 5 to 10 mg daily for 6 months
Oxybutynin
5 mg Oxybutynin twice a daily for 6 months
Oxybutynin
Oxybutynin 5 to 10 mg daily for 6 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Minirin
Minirin 5 to 10 mg daily for 6 months
Oxybutynin
Oxybutynin 5 to 10 mg daily for 6 months
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Nocturnal enuresis
* Candidate for pharmacological treatment
Exclusion Criteria
* Impossibility of follow up during the study period
* History of seizure
* History of rheumatologic disorders such as sjogren's disease
5 Years
14 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hormozgan University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hamidreza Mahboobi
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hamidreza Mahboobi, M.D
Role: PRINCIPAL_INVESTIGATOR
Hormozgan University of Medical Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shahid Mohammadi hospital
Bandar Abbas, Hormozgan, Iran
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ghasemi K, Esteghamati M, Mohammadzadeh M, Zare S. Desmopressin versus Oxybutynin for Nocturnal Enuresis in Children in Bandar Abbas: A Randomized Clinical Trial. Electron Physician. 2016 Mar 25;8(3):2187-93. doi: 10.19082/2187. eCollection 2016 Mar.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
92.121.505
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.